Objectives: Hereditary haemorrhagic telangiectasia (HHT) affects 1 in 5-8,000
Introduction
Hereditary haemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome), is a relatively common genetic condition affecting 1 in 5-8,000 Europeans 1, 2 . Most affected individuals are unaware of their diagnosis 3, 4 . This is particularly true of younger individuals since the main clinical manifestations of recurrent nosebleeds, characteristic mucocutaneous telangiectasia and anaemia are either considered normal (nosebleeds), or become prominent later in life 5, 6 . HHT-affected individuals also commonly have silent arteriovenous malformations (AVMs). Screening programmes in asymptomatic individuals indicate that these occur at significant frequencies. Pulmonary AVMs are now estimated to affect at least 48% of HHT patients 7 ; cerebral AVMs up to 10% 8 ; hepatic AVMs approximately 30% 9 , with spinal AVM frequencies estimated at between 0.3-1%.
In normal pregnancy, complex physiological vasodilatory responses are associated with the increase in cardiac output that approaches 50% by the end of the second trimester 10 .
Cardiac chamber 10 and aortic 11 dimensions increase in normal pregnancies. Effects on the HHT vascular bed would be predicted.
Two series of pregnancy outcomes in HHT have been reported. Goodman et al performed a retrospective study of 40 HHT patients (recruited from an ENT clinic) compared to 80 controls matched for age, ethnicity, religion and health care 12 . The rates of miscarriage per pregnancy (14.4% versus 9.9%, HHT figures given first), and abnormal outcome per individual (50% versus 42.3%) did not differ statistically between the two groups. In a retrospective series of 161 pregnancies in HHT-affected women and family members recruited from a clinic with a PAVM bias, no excess rate of miscarriage was reported 13 . There was a significant increase in maternal complications in women with PAVMs: overall, 2 maternal deaths (PAVM haemorrhage), 6 cases of PAVM shunt deterioration and three maternal strokes were reported 13 .
In addition to these series, there have been case reports of HHT complications during pregnancy: Pulmonary AVM-related haemorrhage [14] [15] [16] [17] [18] [19] [20] , and growth of pulmonary AVMs Here we report an approach that allowed two major questions to be addressed: First, whether estimates of absolute risks of pregnancy could be established; and second, whether recognition of at-risk status might improve outcome in the event of a life threatening HHT complication during pregnancy. The findings were utilised to develop recommendations for pregnancy management. (Figure 1 ), visceral involvement, and family history 30 : All individuals were screened for the presence of pulmonary AVMs using imaging (thoracic CT scan unless the chest x-ray was diagnostic), and all individuals with pulmonary AVMs large enough for treatment underwent coil embolization as described previously 31 . In keeping with current recommended clinical practice in Europe, screening of asymptomatic individuals for the presence of cerebral 32 or hepatic 9 vascular malformations was not performed.
Methods

Study setting and participants
Pregnancy groups
While a prospective study was initiated, only 18 women had pregnancies following review by us. Most pregnancies occurred in women prior to review. In the majority of these women, pregnancies occurred prior to PAVM diagnosis which in turn, was usually prior to the diagnosis of HHT 3 . In order to record life-threatening events that were less likely to have occurred in women who survived their pregnancies, we also studied the pregnancies of the women's first degree relatives who were affected by HHT as denoted by recurrent nosebleeds, telangiectasia or other HHT complications. 222 pregnancies occurred in these 86 HHT-affected women. Again, the majority of pregnancies occurred prior to HHT/PAVM recognition. Table 1 summarises the features of these three groups. Women in the prospective group received intervention and pre-pregnancy advice that may have influenced pregnancy outcomes. Fifteen underwent PAVM embolisation treatment prior to pregnancy. In addition, pregnant women, their obstetric team, and local doctors were provided with advice developed following our earlier manuscript 13 , and subsequent discussions. This information advised of the small risk of haemoptysis to be considered a medical emergency if it occurred in pregnancy, and the potential presence of cerebral and spinal AVMs. We suggested that women with HHT were managed as though they had cerebral AVMs, noting that theoretical concerns, and evidence of rupture of cerebral AVMs and aneurysms during vaginal and Caesarean deliver, influence general obstetric anaesthetic practice 33, 34 . At our institution, a prolonged second stage of labour was avoided to minimise Valsalva manoeuvres, and if general anaesthesia was required, modified induction regimes with opiates were used to attenuate the hypertensive response to laryngoscopy. Although the anaesthetic technique was protective for the mother, placental transfer of opiate is well recognised and thus this was not ideal for the baby. At our institution, we withheld regional analgesia/anaesthesia unless spinal AVMs had been excluded..
Retrospective and relatives groups:
Occurrence and outcome of all pregnancies were documented during a detailed personal history (retrospective group) or family history (relatives group). None of the women in these groups had received detailed information of possible pregnancy risks. Where haemoptysis, stroke or maternal death had occurred, with consent from the proband, further information was obtained from the relevant medical, obstetric, radiological or pathology services. Histopathology samples and original imaging were reviewed.
Statistics
Basic statistics and univariate analyses were performed using Prism 4 (Graph Pad 
Results
Complications occurred in first (n=6), second (n=7) and third or greater (n=5) pregnancies, as summarised in Table 2 . 
Pulmonary AVM haemorrhage
There were six PAVM haemorrhages in the prospective and retrospective groups, as detailed in Figure 2A , B. Four of these women had had previous PAVM embolization at four different institutions. Two women were treated by embolization of pulmonary or systemic arterial supply to the PAVM, and two women underwent emergency thoracotomy for surgical resection or cauterisation of PAVMs. Major haemoptysis was also reported in six relatives, leading to the two previously reported cases of maternal death 13 , and two further fatalities in the first post partum year.
Overall, the rate of life-threatening bleeds from pulmonary AVMs was 1.36% (0.17, 
Strokes in pregnancy
There were three significant strokes during pregnancy in the patient group. Two occurred in the first trimester, were of ischaemic aetiology and were attributed to paradoxical emboli through pulmonary AVMs 3 that were subsequently embolised. A third was a subarachnoid haemorrhage as previously reported 13 . All women made good recoveries and the pregnancies subsequently proceeded normally.
In relatives, three third trimester strokes were also reported. Two were fatal, one due to rupture of an internal carotid artery aneurysm at 7 months gestation ( Figure 2C) , and a second due to undefined pathology during childbirth leading to maternal death. A third resulted in a hemiplegic stroke in the 7 th month of pregnancy. An abnormal vessel was surgically resected after a Cesarean section under general anesthesia, and the woman went on to have a further uncomplicated pregnancy.
Maternal death
No maternal deaths occurred in the patient group comprising a small prospective group of 23 pregnancies, and large retrospective group of 239 pregnancies for which survival was a prerequisite. In the relatives' group which did not have this 'survival to review' bias, there were five deaths. One was due to an acute transmural myocardial infarction in a 16 year old at 32 weeks gestation ( Figure 2D ), two deaths were due to haemoptysis 13 , and two were due to haemorrhagic strokes. The overall maternal death rate was 1.00% of pregnancies (95% confidence limits 0.13, 1.92, Table 1 ); 2.51% (0.32, 4.71) of women.
All deaths in our series occurred in women previously considered well and not under medical review for HHT.
In the event of a life-threatening event, there was a statistically significant improvement in survival in women in whom the diagnosis of HHT or PAVMs had been made previously: Of the 17 women with haemoptysis/haemothorax, stroke or myocardial infarction, five had a known diagnosis of PAVM (for haemoptysis) or HHT at the time, and all five survived with their infants. Of the twelve other women, whose haemorrhagic complications during pregnancy occurred prior to the diagnosis of HHT or PAVMs, seven died and five survived (p =0.041 Fisher's exact test).
Discussion
Between 1985 and 2005, all cause UK maternal mortality rates ranged from 0.010-0.014% 38 . Our data demonstrate that in HHT, while the vast majority of pregnancies proceed uneventfully, the mortality rate is significantly increased, due to PAVM haemorrhage, strokes and myocardial infarction. Life-threatening events occurred in women who had few manifestations of HHT prior to pregnancy, but prior awareness of HHT/PAVM diagnosis was associated with a statistically improved survival outcome for mother (and infant) in the event of a major complication.
The strengths of this study include large numbers examined for a rare condition: This is particularly important since it is not possible to ascertain HHT-related death rates from recent Confidential Enquiries into Maternal and Child Health (CEMACH) reports in which events would be classified as 'other indirect' causes of death 38 . Furthermore, most individuals with HHT are unaware of their diagnosis, and maternal death in pregnancy may be a precipitation for family review and referral. Previous small series are therefore likely to have over-represented maternal risks due to ascertainment bias, as in our previous pregnancy series 13 . However the overall types of complications are similar to those previously reported here, namely PAVM-related haemorrhage, and stroke.
Potential biases present included referral bias (pregnancy complications in a relative biasing the referring physician towards referral), and the pulmonary AVM focus of our clinical practice. In addition, in order to reduce bias due to intervention, or survival to review, it was essential to capture data in relatives in whom the diagnosis of HHT was made from a reported history or transmission to children. This method is likely to have led to a failure to capture all affected individuals. For these reasons, we suspect that the overall risks of pregnancy may be revised downwards. Importantly however, we are aware of three other relatively recent UK PAVM-haemorrhage deaths in pregnancy that
were not captured by our series.).
Many complications in the HHT pregnancies occurred in the second and third trimesters, at the time of reduced peripheral resistance and increased cardiac output, and reduced systemic vascular resistance 10 . Similar timings are observed in haemorrhages from non-HHT cerebral AVMs 27 . We therefore anticipate that the haemorrhages in our population occurred as a result of general pregnancy responses leading to aberrant haemodynamic and other stresses in an abnormal vascular bed, as opposed to an HHT-specific response to pregnancy.
The reported survival advantage of prior recognition of HHT/PAVM status is encouraging. We presume this operates by heightened patient and physician awareness of potential complications and novel symptoms. While emergency intervention is likely to need to be managed on a case-by-case basis, prior recognition (and pre-planning of management in the event of a complication) may be sufficient for local obstetric services to optimise outcomes in the event of a rare complication, including emergency delivery where maternal survival is unlikely.
The data allow some preliminary guidance for clinical management, which is summarised in Table 3 . In almost all cases in this series, and those known subsequently to us, there was sufficient time after the onset of symptoms to allow for hospital admission and intervention. Thus all pregnancies with HHT should be considered high risk, and women
should be advised about the small but serious risks, though re-assured that these appear less threatening where medical and obstetric services are aware of the complications.
Advice to all maternity health care providers needs to emphasise the need for immediate referral should haemoptysis or dyspnoea occur.
In general for HHT-affected adults, screening and treatment of pulmonary AVMs is recommended to reduce later complications such as paradoxical embolic stroke and haemorrhage. The management of asymptomatic women found to have pulmonary AVMs during pregnancy is not as clear-cut as for non-pregnant individuals. During pregnancy, our data have shown that the risk of pulmonary AVM-associated complications is low; furthermore, there is no reported evidence that embolization of pulmonary AVMs during pregnancy in women who have not experienced a complication reduces the risk of haemorrhage or ischaemic stroke in the second and third trimester.
The risks associated with PAVM embolization are small but the procedure does involve ionizing radiation and, as with any intervention, there is the potential for complications.
For these reasons, we do not feel that PAVM screening and treatment of asymptomatic individuals during pregnancy is justified.
Screening for cerebral AVMs could simplify obstetric anaesthetic management for the 90% of individuals in whom no cerebral AVM or aneurysm would be detected, but there are several concerns. First, such scans may lead to false reassurance since small cerebral AVMs are not detectable by MRI, and pregnancy itself precipitates the growth of many AVMs such that pre or early-pregnancy assessment of AVM presence or size may not be relevant to the situation in late pregnancy or delivery. Secondly, up to one in ten women will be found to have an asymptomatic cerebral AVM. European risk-benefit analyses of treatment of asymptomatic cerebral AVMs in the general HHT population are not interpreted in favour of treatment 33 . The published literature, and our current data, do not suggest that pregnancy substantially alters these considerations. Thus up to 10% of women would be faced with the identification of cerebral AVMs for which treatment would not be recommended at the current time. For any individual, it is difficult to judge how well they would cope with this knowledge 40 . Whether the obstetric anaesthetic considerations justify subjecting women in pregnancy to these concerns needs further informed discussion.
Spinal AVMs in non-HHT individuals have been punctured by epidural needles resulting in paraparesis 41 . This has led some obstetric anaesthetic practices, including our own, to avoid regional anaesthesia, in turn, increasing the likelihood of a general anaesthetic.
Were spinal AVMs to be excluded, epidurals could be employed with greater reassurance. Furthermore, in the unlikely event that spinal AVMs were detected, pregnancy management could be optimised to minimise risks of obstructed venous drainage, and since few bleeds have been reported, the associated anxiety would be substantially lower than for detection of a cerebral AVM. 
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Legends for Figures
There was no evidence of vasculitis. Sections of the right ventricle were normal. We speculate that an undiagnosed pulmonary AVMs contributed to her death, causing a paradoxical embolic coronary artery thrombosis which had dissipated at the time of death 24 hours later: HHT patients have a venous prothrombotic tendency via elevated Factor VIII levels 37 , and pulmonary AVMs provide a conduit for paradoxical emboli. 
